In short
Sultiame, also known as Ospolot, is a medication that has been the subject of several clinical trials investigating its efficacy in treating various conditions. These trials have primarily focused on its use in childhood epilepsy syndromes and, more recently, in obstructive sleep apnea (OSA) in adults. Researchers are exploring different doses, formulations, and applications of Sultiame to better understand its potential benefits and side effects in these medical conditions.
At a glance
- Conditions Studied
- Obstructive Sleep Apnea (OSA), Childhood Epilepsy Syndromes, Benign Epilepsy with Centro-Temporal Spikes (BECTS)
- Dosages Tested
- 50 mg, 100 mg, 200 mg, 300 mg
- Primary Outcomes
- Changes in AHI, Pharmacokinetic parameters, EEG improvements
- Study Designs
- Randomized, double-blind, placebo-controlled; Open-label pharmacokinetic study; Exploratory EEG study
- Safety Monitoring
- Adverse events, TEAEs, Serious TEAEs, Discontinuations due to adverse events
- Potential Mechanisms
- Inhibition of carbonic anhydrase enzymes, Intracellular acidification
What is Sulthiame?
Sulthiame, also known by its brand name Ospolot, is a medication that has been used since the 1960s in several countries, including Germany, Austria, Switzerland, Israel, Australia, and Japan. It is primarily used as an antiepileptic drug, which means it helps control seizures in people with epilepsy. Sulthiame has gained particular importance in treating certain types of childhood epilepsy.
Medical Conditions Treated with Sulthiame
Sulthiame is used to treat several medical conditions:
- Childhood Epilepsy Syndromes: Sulthiame has become the first-choice treatment for benign focal epilepsies of childhood in some countries. It is particularly effective in treating a condition called Benign Epilepsy with Centro-Temporal Spikes (BECTS), also known as Rolandic epilepsy.
- Obstructive Sleep Apnea (OSA): Recent clinical trials are exploring the use of Sulthiame in treating moderate to severe obstructive sleep apnea in adults.
How Sulthiame Works
Sulthiame works by inhibiting an enzyme called carbonic anhydrase, particularly a subtype known as cytosolic hCA II. This inhibition leads to a slight increase in acidity inside cells, which is thought to stabilize neurons (brain cells) that might otherwise trigger seizures. This mechanism helps explain its effectiveness in controlling epileptic seizures.
Current Clinical Trials
Several clinical trials are currently underway to further explore the uses and effects of Sulthiame:
- Obstructive Sleep Apnea Study: A large-scale trial is evaluating the efficacy, safety, and tolerability of three different doses of Sulthiame (100 mg, 200 mg, and 300 mg) compared to a placebo in adults with moderate to severe obstructive sleep apnea.
- Pharmacokinetics Study: A small pilot study is investigating how Sulthiame is processed by the body (its pharmacokinetics) and its tolerability in healthy volunteers. This study aims to help design future clinical trials and develop new pediatric formulations.
- EEG Effects in Childhood Epilepsy: A study is exploring how quickly Sulthiame affects brain activity (measured by EEG) in children with epilepsy syndromes that are activated during sleep.
- Comparison with Levetiracetam: A study is comparing the effectiveness of Sulthiame with another antiepileptic drug, Levetiracetam, in children with BECTS.
Dosage and Administration
Sulthiame is typically taken orally in the form of film-coated tablets. The dosage can vary depending on the condition being treated and the patient's age:
- For epilepsy in children, the dosage is determined by the treating physician based on the child's specific needs.
- In the obstructive sleep apnea trial, adults are being given once-daily doses of 100 mg, 200 mg, or 300 mg.
- Currently available tablet strengths are 50 mg and 200 mg, which may not always allow for precise dosing in young children. Research is ongoing to develop more suitable pediatric formulations.
Potential Side Effects
As with all medications, Sulthiame can cause side effects. The ongoing clinical trials are closely monitoring for adverse events. Common side effects may include:
- Gastrointestinal issues
- Headache
- Dizziness
- Fatigue
It's important to note that the full range of potential side effects is still being studied, particularly for its use in obstructive sleep apnea.
Comparisons with Other Medications
One ongoing study is directly comparing Sulthiame with Levetiracetam, another antiepileptic drug, for the treatment of BECTS in children. This study aims to determine if Levetiracetam is as effective as Sulthiame, which has been a standard treatment for this condition. The study is also comparing the safety, tolerability, cognitive effects, and impact on EEG patterns of these two medications.